Clinical Trial Update: A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial evaluating aliskiren for prevention of major cardiovascular events in elderly individuals was terminated; results were posted in 2014…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease

Drugs mentioned

• Aliskiren (Aliskiren)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cardiovascular Events | Phase 3 | Status: TERMINATED | Results posted: 2014-04-08